Karim S. Fizazi

机构：Université Paris-Sud, Université de Lille, Université Paris-Saclay, Institut Gustave Roussy, Centre Oscar Lambret · ORCID：0000-0002-6068-9474

发表论文 1574 篇 · 总被引 86673 次 · h-index 127

代表论文

Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis (2025 · European Urology · 被引 7)
Androgen deprivation therapy and radiotherapy with or without cabazitaxel in very-high risk localized prostate cancer: First results of the PEACE-2 randomized phase III trial. (2026 · Journal of Clinical Oncology · 被引 3)
Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP) (2025 · Future Oncology · 被引 3)
Use of concomitant G-CSF in maintaining efficacious dose and safe delivery of docetaxel in combination with darolutamide in ARASENS: A phase III study (2026 · European Journal of Cancer · 被引 2)
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer (2025 · Nature Communications · 被引 2)
Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS Trial (2025 · European Urology Oncology · 被引 2)